

Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation

Zachary D. Epstein-Peterson,¹ Esther Drill,² Umut Aypar,³ Connie Lee Batlevi,¹ Philip Caron,¹ Ahmet Dogan,³ Pamela Drullinsky,¹ John Gerecitano,^{1*} Paul A. Hamlin,¹ Caleb Ho,^{3*} Allison Jacob,⁴ Ashlee Joseph,¹ Leana Laraque,¹ Matthew J. Matasar,¹ Alison J. Moskowitz,¹ Craig H. Moskowitz,^{1*} Chelsea Mullins,^{4*} Colette Owens,¹ Gilles Salles,¹ Heiko Schöder,⁵ David J. Straus,¹ Anas Younes,^{1*} Andrew D. Zelenetz¹ and Anita Kumar¹

¹Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; ²Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY; ³Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY; ⁴Adaptive Biotechnologies, Seattle, WA and ⁵Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

*Current address JG: *The Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ, USA*

*Current address CH: *Loxo Oncology, Inc., Stamford, CT, USA*

*Current address CM: *Notch Therapeutics, Seattle, WA, USA*

*Current address CHM: *Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA*

*Current address AY: *AstraZeneca Pharmaceuticals, LP, Wilmington, DE, USA*

Correspondence: A. Kumar
kumara@mskcc.org

Received: May 9, 2024.

Accepted: May 9, 2024.

<https://doi.org/10.3324/haematol.2024.285845>

©2024 Ferrata Storti Foundation

Published under a CC BY-NC license



Supplemental Table 1. High risk status vs *TP53* alteration.

<i>TP53</i> alteration	High Risk [†]		Total	P value ¹
	N	Y		
				0.006
Wildtype	11 (73%)	16 (59%)	27 (64%)	
Deletion	4 (27%)	1 (3.7%)	5 (12%)	
Mutation	0 (0%)	1 (3.7%)	1 (2.4%)	
Mutation and deletion/loss of heterozygosity	0 (0%)	9 (33%)	9 (21%)	
Total	15 (100%)	27 (100%)	42 (100%)	

[†]All samples with bi-allelic inactivation of *TP53* are included in the high-risk group per protocol

¹Fisher's exact test

N, no; Y, yes